Ad
Search
Generic filters
Filter by content type
Taxonomy terms

CFRX – ContraFect Corp

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2.67

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 3.67

Low: 1

High: 7

Total Analysts: 4

Company Profile

ContraFect Corporation is a late clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa and has demonstrated potent in vivo activity against extensively drug-resistant (XDR) strains. It has developed an, engineered variant of exebacase, known as CF-296. It is conducting further in vitro and in vivo characterization of CF-296 to evaluate the full profile of this compound.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses